DK0784632T3 - Fremgangsmåde til udvinding af højren von Willebrand-faktor - Google Patents

Fremgangsmåde til udvinding af højren von Willebrand-faktor

Info

Publication number
DK0784632T3
DK0784632T3 DK95935890T DK95935890T DK0784632T3 DK 0784632 T3 DK0784632 T3 DK 0784632T3 DK 95935890 T DK95935890 T DK 95935890T DK 95935890 T DK95935890 T DK 95935890T DK 0784632 T3 DK0784632 T3 DK 0784632T3
Authority
DK
Denmark
Prior art keywords
von willebrand
willebrand factor
rvwf
free
extracting
Prior art date
Application number
DK95935890T
Other languages
English (en)
Inventor
Bernhard Fischer
Hans-Peter Schwarz
Manfred Reiter
Friedrich Dorner
Peter Turecek
Johann Eibl
Uwe Schlokat
Wolfgang Mundt
Renate Den-Bouwmeester
Artur Mitterer
Falco-Guenter Falkner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Application granted granted Critical
Publication of DK0784632T3 publication Critical patent/DK0784632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95935890T 1994-10-04 1995-10-02 Fremgangsmåde til udvinding af højren von Willebrand-faktor DK0784632T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4435485A DE4435485C1 (de) 1994-10-04 1994-10-04 Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
PCT/EP1995/003892 WO1996010584A1 (de) 1994-10-04 1995-10-02 Verfahren zur gewinnung von hochreinem von willebrand-faktor

Publications (1)

Publication Number Publication Date
DK0784632T3 true DK0784632T3 (da) 1999-08-30

Family

ID=6529944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935890T DK0784632T3 (da) 1994-10-04 1995-10-02 Fremgangsmåde til udvinding af højren von Willebrand-faktor

Country Status (11)

Country Link
US (4) US5854403A (da)
EP (1) EP0784632B1 (da)
JP (1) JP3701028B2 (da)
AT (1) ATE175424T1 (da)
AU (1) AU698334B2 (da)
CA (1) CA2201714C (da)
DE (2) DE4435485C1 (da)
DK (1) DK0784632T3 (da)
ES (1) ES2128090T3 (da)
GR (1) GR3029837T3 (da)
WO (1) WO1996010584A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880327A (en) * 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2000016872A1 (en) 1998-09-21 2000-03-30 Purdum Howard E Methods and apparatus for processing temperature sensitive materials
AU7619500A (en) * 1999-09-28 2001-04-30 Us Transgenics, Inc. Transgenic vwf and vwf-related polypeptides, transgenics, methods, compositions,uses and the like relating thereto
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
JP5112692B2 (ja) * 2003-07-07 2013-01-09 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル フォンビルブランド因子（ｖｗｆ）マルチマーを検出する方法およびシステム
US7771660B2 (en) * 2004-05-04 2010-08-10 University Of North Carolina At Chapel Hill Electrophoretic interactive spectral methods and devices for the detection and/or characterization of biological particles
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006029258A2 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
ES2434035T3 (es) 2004-12-27 2013-12-13 Baxter International Inc. Conjugados de polímero-factor von Willebrand
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
DK2167117T3 (da) 2007-06-13 2012-11-19 Csl Behring Gmbh Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
AU2014202595A1 (en) * 2007-12-28 2014-06-05 Baxalta GmbH Recombinant VWF Formulations
US11197916B2 (en) * 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858A (zh) 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
AU2009307648C1 (en) * 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US20120148557A1 (en) 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP5876416B2 (ja) 2009-11-13 2016-03-02 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
AU2012322949B2 (en) * 2011-10-14 2015-07-02 Takeda Pharmaceutical Company Limited Protein purification by anion exchange chromatography
US9393289B2 (en) 2011-10-18 2016-07-19 Csl Behring Gmbh Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII
DK2768521T3 (da) 2011-10-18 2016-10-24 Csl Behring Gmbh Kombineret anvendelse af et sulfateret glykosamin-glykan og en hyaluronidase til forbedring af bio-rådigheden af Faktor VIII
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
AU2014346343B2 (en) 2013-11-08 2018-05-10 Csl Ltd. New method to concentrate von Willebrand factor or complexes thereof
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
JP7307047B2 (ja) 2017-07-07 2023-07-11 武田薬品工業株式会社 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
KR20200038309A (ko) 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
NL8500961A (nl) * 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
DE3904354A1 (de) * 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
DE69027187T2 (de) * 1989-06-15 1996-10-31 Rorer Int Overseas Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
US5312747A (en) * 1990-12-17 1994-05-17 Li Yu Teh Isolation, purification and utilization of sialidase-L in the synthesis of 2,7-anhydro-N-acetylneuraminic acid and for the selective cleavage of sialylα2-3 D-galactose linkage
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
IT1256622B (it) * 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Also Published As

Publication number Publication date
JP3701028B2 (ja) 2005-09-28
DE4435485C1 (de) 1996-03-21
DE59504750D1 (de) 1999-02-18
ATE175424T1 (de) 1999-01-15
JPH11509721A (ja) 1999-08-31
US5877152A (en) 1999-03-02
WO1996010584A1 (de) 1996-04-11
US5854403A (en) 1998-12-29
US6103693A (en) 2000-08-15
EP0784632B1 (de) 1999-01-07
GR3029837T3 (en) 1999-06-30
US5880265A (en) 1999-03-09
ES2128090T3 (es) 1999-05-01
AU698334B2 (en) 1998-10-29
CA2201714C (en) 2002-07-02
CA2201714A1 (en) 1996-04-11
EP0784632A1 (de) 1997-07-23
AU3803195A (en) 1996-04-26

Similar Documents

Publication Publication Date Title
DK0784632T3 (da) Fremgangsmåde til udvinding af højren von Willebrand-faktor
RU93046317A (ru) Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции
Calvete et al. A procedure for the large-scale isolation of major bovine seminal plasma proteins
Bhakdi et al. Detection of amphiphilic proteins and peptides in complex mixtures. Charge-shift crossed immunoelectrophosis and two-dimensional charge-shift electrophoresis
CA2099138A1 (en) Chondroitinase, Process for Preparing the Same, and Pharmaceutical Composition Comprising the Same
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
RU95115239A (ru) Аналог эритропоэтина
KR920701255A (ko) 에리쓰로포이에틴 동형체(eryihropoietin isoform)
DK0620854T3 (da) Ekspression og oprensning af rekombinant opløselig vævsfaktor
HUP0202124A2 (hu) Eljárás gyógyszerészetileg aktív fehérjék tisztítására kationcserélő kromatográfiával
CA2282841C (en) A method of purifying factor viii/vwf-complex by means of cation exchange chromatography
EP0469985A1 (en) Process for manufacturing von Willebrand factor having a very high purity
CA2480226A1 (en) Stable pharmaceutical composition containing factor viii
ES2171086T3 (es) Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
Kotite et al. Subunit structure of rabbit testosterone estradiol-binding globulin.
IE852681L (en) Monoclonal antibodies for cancer
ATE69727T1 (de) Zusammensetzung zur behandlung von an haemophilia- a-inhibitor leidenden kranken.
DK0419878T3 (da) Nye aprotinin-varianter og genteknologisk fremgangsmåde til mikrobiel fremstilling af disse varianter i homogent processeret form
GR3025929T3 (en) Ein isolation and purification of lung surfactant prot
KR960705580A (ko) 단백질 C 또는 활성화 단백질 C를 안정화시키는 방법 및 안정화된 조성물(Method of stabilizing protein C or activated protein C and stabilized composition)
KR860008270A (ko) α-인터페론의 제조 및 정제 방법
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
Tillement et al. Effect of sodium chlorophenoxyisobutyrate on the binding of vitamin K antagonists to human albumin in vitro
Ishaq et al. Purification and identification of antigenic polypeptides of Sm and RNP antigens of goat liver
TR200002611T2 (tr) Beta-lipotropin ve kullanımları